Verrica Pharmaceuticals Statistics
Share Statistics
Verrica Pharmaceuticals has 98.68M shares outstanding. The number of shares has increased by 1.44% in one year.
| Shares Outstanding | 98.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.59% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 49.03M |
| Failed to Deliver (FTD) Shares | 1.55K |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 4.37M, so 9.59% of the outstanding shares have been sold short.
| Short Interest | 4.37M |
| Short % of Shares Out | 9.59% |
| Short % of Float | 16.07% |
| Short Ratio (days to cover) | 4.35 |
Valuation Ratios
The PE ratio is -4.95 and the forward PE ratio is -1.54.
| PE Ratio | -4.95 |
| Forward PE | -1.54 |
| PS Ratio | 64.77 |
| Forward PS | 1.3 |
| PB Ratio | 16.79 |
| P/FCF Ratio | -8.52 |
| PEG Ratio | n/a |
Enterprise Valuation
Verrica Pharmaceuticals Inc. has an Enterprise Value (EV) of 307.87M.
| EV / Earnings | -4.6 |
| EV / Sales | 60.08 |
| EV / EBITDA | -4.95 |
| EV / EBIT | -4.68 |
| EV / FCF | -7.91 |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 2.2.
| Current Ratio | 4.55 |
| Quick Ratio | 4.49 |
| Debt / Equity | 2.2 |
| Total Debt / Capitalization | 68.8 |
| Cash Flow / Debt | -0.89 |
| Interest Coverage | -16.6 |
Financial Efficiency
Return on equity (ROE) is -3.39% and return on capital (ROIC) is -100.74%.
| Return on Equity (ROE) | -3.39% |
| Return on Assets (ROA) | -0.82% |
| Return on Capital (ROIC) | -100.74% |
| Revenue Per Employee | 51.24K |
| Profits Per Employee | -669.95K |
| Employee Count | 100 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.73 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -87.52% in the last 52 weeks. The beta is 1.46, so Verrica Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.46 |
| 52-Week Price Change | -87.52% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 4.69 |
| Relative Strength Index (RSI) | 32.8 |
| Average Volume (20 Days) | 879.73K |
Income Statement
In the last 12 months, Verrica Pharmaceuticals had revenue of $5.12M and earned -$67.00M in profits. Earnings per share was $-1.48.
| Revenue | 5.12M |
| Gross Profit | 4.38M |
| Operating Income | -65.76M |
| Net Income | -67.00M |
| EBITDA | -62.20M |
| EBIT | -65.76M |
| Earnings Per Share (EPS) | -1.48 |
Balance Sheet
The company has $69.55M in cash and $45.51M in debt, giving a net cash position of $24.04M.
| Cash & Cash Equivalents | 69.55M |
| Total Debt | 45.51M |
| Net Cash | 24.04M |
| Retained Earnings | -230.45M |
| Total Assets | 32.93M |
| Working Capital | 7.16M |
Cash Flow
In the last 12 months, operating cash flow was -$38.58M and capital expenditures -$362.00K, giving a free cash flow of -$38.94M.
| Operating Cash Flow | -38.58M |
| Capital Expenditures | -362.00K |
| Free Cash Flow | -38.94M |
| FCF Per Share | -0.86 |
Margins
Gross margin is 85.44%, with operating and profit margins of -1.28K% and -1.31K%.
| Gross Margin | 85.44% |
| Operating Margin | -1.28K% |
| Pretax Margin | -1.31K% |
| Profit Margin | -1.31K% |
| EBITDA Margin | -1.21K% |
| EBIT Margin | -1.28K% |
| FCF Margin | -759.93% |
Dividends & Yields
VRCA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -194.74% |
| FCF Yield | -52.27% |
Analyst Forecast
The average price target for VRCA is $6, which is 689.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $6 |
| Price Target Difference | 689.5% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -18.75 |
| Piotroski F-Score | 3 |